四環醫藥：附屬自主研發創新藥新適應症獲批開展III期臨床試驗 X
15/04/2026 12:15
<匯港通訊>    四環醫藥(00460)宣布，集團旗下非全資附屬軒竹生物(02575)自主研發的創新藥安奈拉唑鈉腸溶片(商品名：安久衛®)近日獲得中國國家藥品監督管理局藥品審評中心批准，開展含安奈拉唑鈉腸溶片的鉍劑四聯療法根除幽門螺桿菌的III期臨床研究。

本次安奈拉唑鈉新適應症III期臨床試驗申請獲批，有助於拓展產品適應症範圍，提升軒竹生物在消化疾病治療領域的影響力，對軒竹生物長遠發展及商業化佈局具有重要意義。 (ST)

(C) Copyright by Infocast Ltd. All Rights Reserved.

Infocast Limited and its information providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.